China API Facility Receives FDA Warning Letter
The agency sent a warning letter to Chongqing Pharma Research Institute Co., Ltd. citing data integrity violations.
FDA sent a warning letter to Chongqing Pharma Research Institute Co., Ltd. on Feb. 14, 2017 that summarized current good manufacturing practice (CGMP) deficiencies found at the company’s Chongqing facility during an inspection conducted from May 16–19, 2016. Inspectors found data integrity problems including failure to maintain laboratory testing data.
During the May 2016 inspection, FDA investigators found audit trails that showed the company had deleted chromatographic sequences and individual injections from computers and repeated analyses until acceptable results were maintained. Out-of-specification results were not investigated and only passing results were documented. “You relied on these manipulated test results and incomplete records to support batch release decisions,” the agency stated in the letter.
FDA requested that the company perform data integrity remediation and provide the agency with a comprehensive investigation of the data and reporting inaccuracies; a risk assessment of the potential effects of observed failures on the quality of product; and a management strategy that details a corrective action and preventive action plan.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
